Actively Recruiting
Evaluating SL-325 Intravenous Therapy Versus Placebo in Adults with Moderate to Severe Crohns Disease in a Randomized, Double-Blind Study
Led by Shattuck Labs, Inc. · Updated on 2026-11-03
232
Participants Needed
20
Research Sites
100 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy of SL-325 in adults with moderate to severely active Crohns disease. This phase 2 randomized, double-blind, placebo-controlled study aims to assess whether SL-325 can improve disease activity in participants who have not responded well to certain prior Crohns disease treatments. The trial is sponsored by Shattuck Labs, Inc. and involves multiple doses of the study drug. Participants will receive SL-325 or a placebo intravenously during the study. The study includes a screening period lasting up to 6 weeks, followed by a 12-week induction treatment phase, a 38-week maintenance phase, and a 52-week long-term extension period. After these treatment phases, there is a 10-week follow-up period to monitor participants. During the trial, participants will undergo various assessments to monitor their disease status and safety. The main outcome measured is the proportion of participants achieving an endoscopic response at Week 12. Additional outcomes include clinical remission rates and monitoring of treatment-emergent adverse events. The total participation may last over two years, including all study periods and follow-up.
CONDITIONS
Brief Title
A Study of SL-325 in Crohn's Disease Patients
Research Team
S
Shattuck Medical Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here